US Patent

US9181257 — Inhibitors of Bruton's tyrosine kinase

Composition of Matter · Assigned to Pharmacyclics LLC · Expires 2026-12-28 · 1y remaining

Vulnerability score 5/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects pyrazolo[3,4-d]pyrimidines that form covalent bonds with Bruton's tyrosine kinase (Btk) and are used to treat various diseases.

USPTO Abstract

Disclosed herein are pyrazolo[3,4-d]pyrimidines that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Drugs covered by this patent

Patent Metadata

Patent number
US9181257
Jurisdiction
US
Classification
Composition of Matter
Expires
2026-12-28
Drug substance claim
Yes
Drug product claim
No
Assignee
Pharmacyclics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.